Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS001 in unresectable or metastatic melanoma
NCT03430297Phase 3Completed
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Feb 2018
- Primary completion
- Jul 2023
- Countries
- 1
01
Overview
A Phase 3 trial of toripalimab in melanoma, sponsored by Shanghai Junshi Biosciences Co., Ltd.. Started Feb 2018; status: completed.
02
Drugs
toripalimab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03430297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03430297.